Mizuho has reaffirmed its stock price target of $40 for Cartesian Therapeutics, indicating confidence in the company's market performance. This decision reflects Mizuho's analysis of Cartesian's business prospects and overall financial health. Investors and market analysts will be closely monitoring the company's developments in the coming months as it continues to navigate the biotechnology sector.
Related Articles
Don't miss out on breaking stories and in-depth articles.